SHEL vs. GSK
Compare and contrast key facts about Shell plc (SHEL) and GlaxoSmithKline plc (GSK).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: SHEL or GSK.
Correlation
The correlation between SHEL and GSK is 0.45, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
SHEL vs. GSK - Performance Comparison
Loading data...
Key characteristics
SHEL:
-0.30
GSK:
-0.51
SHEL:
-0.13
GSK:
-0.46
SHEL:
0.98
GSK:
0.94
SHEL:
-0.26
GSK:
-0.42
SHEL:
-0.61
GSK:
-0.73
SHEL:
7.92%
GSK:
16.38%
SHEL:
23.01%
GSK:
26.98%
SHEL:
-67.46%
GSK:
-55.21%
SHEL:
-9.43%
GSK:
-15.75%
Fundamentals
SHEL:
$197.06B
GSK:
$78.77B
SHEL:
$4.38
GSK:
$2.02
SHEL:
15.16
GSK:
18.50
SHEL:
1.46
GSK:
0.36
SHEL:
0.70
GSK:
2.50
SHEL:
1.10
GSK:
4.01
SHEL:
$281.07B
GSK:
$31.53B
SHEL:
$42.59B
GSK:
$22.56B
SHEL:
$54.83B
GSK:
$8.24B
Returns By Period
In the year-to-date period, SHEL achieves a 7.09% return, which is significantly lower than GSK's 11.71% return. Over the past 10 years, SHEL has outperformed GSK with an annualized return of 5.37%, while GSK has yielded a comparatively lower 2.89% annualized return.
SHEL
7.09%
6.91%
1.44%
-6.74%
21.17%
5.37%
GSK
11.71%
7.88%
5.12%
-13.71%
1.42%
2.89%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
SHEL vs. GSK — Risk-Adjusted Performance Rank
SHEL
GSK
SHEL vs. GSK - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Shell plc (SHEL) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
SHEL vs. GSK - Dividend Comparison
SHEL's dividend yield for the trailing twelve months is around 4.19%, which matches GSK's 4.15% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
SHEL Shell plc | 4.19% | 4.39% | 3.76% | 3.48% | 3.78% | 5.44% | 6.14% | 5.48% | 4.79% | 5.88% | 6.98% | 4.72% |
GSK GlaxoSmithKline plc | 4.15% | 4.60% | 3.75% | 4.78% | 4.92% | 5.49% | 4.28% | 5.55% | 5.72% | 7.06% | 5.96% | 6.09% |
Drawdowns
SHEL vs. GSK - Drawdown Comparison
The maximum SHEL drawdown since its inception was -67.46%, which is greater than GSK's maximum drawdown of -55.21%. Use the drawdown chart below to compare losses from any high point for SHEL and GSK. For additional features, visit the drawdowns tool.
Loading data...
Volatility
SHEL vs. GSK - Volatility Comparison
The current volatility for Shell plc (SHEL) is 6.46%, while GlaxoSmithKline plc (GSK) has a volatility of 7.78%. This indicates that SHEL experiences smaller price fluctuations and is considered to be less risky than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
SHEL vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between Shell plc and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SHEL vs. GSK - Profitability Comparison
SHEL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Shell plc reported a gross profit of 12.71B and revenue of 69.23B. Therefore, the gross margin over that period was 18.4%.
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, GlaxoSmithKline plc reported a gross profit of 5.58B and revenue of 7.52B. Therefore, the gross margin over that period was 74.2%.
SHEL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Shell plc reported an operating income of 9.47B and revenue of 69.23B, resulting in an operating margin of 13.7%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, GlaxoSmithKline plc reported an operating income of 2.22B and revenue of 7.52B, resulting in an operating margin of 29.5%.
SHEL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Shell plc reported a net income of 4.78B and revenue of 69.23B, resulting in a net margin of 6.9%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, GlaxoSmithKline plc reported a net income of 1.62B and revenue of 7.52B, resulting in a net margin of 21.6%.